Gerngross biotech Ankyra Therapeutics nabs $45M series B to jump into the clinic, hires new CMO
Gerngross biotech Ankyra Therapeutics nabs $45M series B to jump [...]
AstraZeneca wields ax, scrapping midphase programs from $1B takeover, Heptares pact in latest quarterly cull
AstraZeneca wields ax, scrapping midphase programs from $1B takeover, Heptares [...]
Adaptimmune’s TCR T-cell therapy clears efficacy bar in rare cancers, teeing up landmark solid tumor filing
Adaptimmune’s TCR T-cell therapy clears efficacy bar in rare cancers, [...]
Using CRISPR to find a new drug target for multiple sclerosis, inflammatory bowel disease
Using CRISPR to find a new drug target for multiple [...]
Vaxxinity, hoping to turn bodies into their own drug factories, makes a subdued Wall Street debut
Vaxxinity, hoping to turn bodies into their own drug factories, [...]
Organon keeps pedal to the metal, buying up Forendo in 3rd deal since spinning out of Merck
Organon keeps pedal to the metal, buying up Forendo in [...]
Genentech, Novome team up to study seaweed-controlled oral cell therapies in IBD
Genentech, Novome team up to study seaweed-controlled oral cell therapies [...]
After snapping up Parexel with Goldman Sachs, EQT doubles down on healthcare with Life Sciences Partners buyout
After snapping up Parexel with Goldman Sachs, EQT doubles down [...]
Immatics’ cell therapy blasts solid tumors in phase 1, but durability spooks investors. Will dialing up the dose help?
Immatics’ cell therapy blasts solid tumors in phase 1, but [...]
Startup Regulonix pursues non-opioid pain drug that indirectly blocks a key ion channel
Startup Regulonix pursues non-opioid pain drug that indirectly blocks a [...]